INNV · InnovAge Holding Corp. · Stock research

Current Thesis

The operating leg has not moved since 2026-05-05: capitation-rate leverage plus resumed PACE enrollment, expressed as FY2026 adjusted-EBITDA guidance of $85–90M (raised from $70–75M) and census of roughly 8,050 participants across 20 centers in six states as of 2026-03-31. What has changed since the 2026-08-12 read is that the price leg repaired itself and the sell-side gap closed at one end. KeyBanc moved to Overweight from Sector Weight on 2026-08-21 with a $13 price target, after management meetings and a visit to a Denver-area PACE center, calling the turnaround complete; the same firm had maintained Hold on 2026-07-20. That is the first covering target printed above the market price in this cycle. The reference close on 2026-08-21 was $10.96 — a Friday, so also the weekly settlement — back above the $10.50 shelf that the 2026-08-11 close of $10.23 had broken on a daily settlement. Narrative state: maturing. The story is known and still working, but the 52-week high of $12.11 has not been retaken since late July, RSI(14) sits at 46.1, and the analyst framing has shifted from "recovery" to "turnaround complete" — which puts the weight on FY2027 guidance rather than on further estimate repair. The 2026-09-08 Q4/FY2026 print is the event that settles it.

Bullish and bearish views on InnovAge Holding Corp.

The model's bull view on InnovAge Holding Corp. (INNV), in brief: KeyBanc, 2026-08-21: Overweight from Sector Weight, $13 target. The bear view: Supply is papered and effective. About 83.2% of the 135,736,393 outstanding as of 2026-04-30 — for resale by TCO Group Holdings, L.P., the Apax Partners / Welsh, Carson vehicle. No lock-up is disclosed and the company receives no proceeds. Target dispersion is now extreme rather… Both cases follow in full.

Bull Case

• KeyBanc, 2026-08-21: Overweight from Sector Weight, $13 target. The note models FY2026 EPS of $0.21 against a trailing-twelve-month loss of $0.09 per share and argues the shares can hold a 15x post-turnaround multiple on barriers to entry and a growth profile above 10%.
• Q3 FY2026, reported 2026-05-05: revenue $251.9M, +15.5% YoY; adjusted EBITDA $30.5M; center-level contribution margin $61.0M.
• Guidance raised the same day to $950–975M revenue and $85–90M adjusted EBITDA, from $925–950M / $70–75M, with an ending-census target of 7,900–8,100.
• Q2 FY2026, reported 2026-02-03: net income $11.8M against a $13.5M year-ago loss on $239.7M revenue, +14.7% YoY — the profitability turn spans more than one quarter.
• FY2025 revenue was $853.70M, +11.76% YoY, with a $30.31M net loss (stockanalysis.com financials, retrieved 2026-08-11). The FY2026 guide steps up on both lines from that base.
• The 2026-07-31 resale prospectus restates ~8,050 participants across 20 centers in six states — nothing filed through end-July discloses a census break.
• The August drawdown did not extend. From the $10.23 close on 2026-08-11 the shares closed $10.96 on 2026-08-21, and RSI(14) at 46.1 is neither washed out nor stretched.

Bear Case

• Supply is papered and effective. About 83.2% of the 135,736,393 outstanding as of 2026-04-30 — for resale by TCO Group Holdings, L.P., the Apax Partners / Welsh, Carson vehicle. No lock-up is disclosed and the company receives no proceeds.
• Target dispersion is now extreme rather than resolved. J.P. Morgan has carried a Sell rating with a $7 target since 2026-02-23; as of 2026-08-11 stockanalysis.com computed the three-analyst average target at $7.00, 31.57% below the then-prevailing price. KeyBanc's $13 sits at the far end of a three-name sample.
• KeyBanc's own note flags potential rate headwinds in fiscal 2027 — the same variable that FY2027 guidance on 2026-09-08 has to address.
• Q3 FY2026 carried a $29.9M GAAP net loss against $30.5M of adjusted EBITDA, with stockanalysis.com attributing part of the gap to increased litigation liability. The reconciliation is where the September print gets judged, not the adjusted headline.
• Sequential census growth was +0.5% QoQ in Q3 FY2026. Enrollment is capacity- and regulator-gated; the ending-census target of 7,900–8,100 is a narrow band around the last reported ~8,050.
• Market capitalisation was $1.39B on 135.74M shares at the 2026-08-11 close, against an FY2026 adjusted-EBITDA guide of $85–90M that has not yet been reported against.
• CMS enrollment freezes at Colorado, California and New Mexico centers broke this equity in 2021–2022. That mechanism has not been retired.

Setup & Price Structure

• Reference close $10.96 on 2026-08-21, against a 52-week high of $12.11 on the adjusted daily series — 9.5% below it. Three-month price change of +52.2%. RSI(14) 46.1.
• The $10.50 shelf that framed the July–August range was lost on the 2026-08-11 daily close of $10.23 and reclaimed by the 2026-08-21 weekly close. It is the level the whole recovery leg is now hung on.
• Overhead reference marks, in order: the $11.18 close of 2026-08-07, the $11.60 last sale printed in the 2026-07-31 resale prospectus, then the $12.11 high.
• Crowding and positioning observables, stated as observables: 83% of the cap table registered for resale since 2026-07-31 with no disclosed lock-up; an earnings print listed for 2026-09-08 by third parties; a mid-40s RSI with price 9.5% under the high, so no momentum extension into that print; three tracked analysts covering a $1.39B-cap name, one of whom flipped bullish two weeks before the print.
• Note the two price series in circulation. The vendor quote page marked a 52-week range of $3.18–$12.64 as of 2026-08-11; the split/dividend-adjusted series used for level-grading here marks the 52-week high at $12.11. Levels in this note are graded against the adjusted series.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — Scheduling press release naming the Q4/FY2026 earnings date. The prior two ran 2025-08-26 and 2024-08-27. Confirms or moves the third-party-listed 2026-09-08 date.
• 2026-09-08 — Q4 and full-year FY2026 results, first FY2027 guidance, year-end census. Tests whether FY2026 adjusted EBITDA lands inside the raised $85–90M band and whether ending census clears 7,900–8,100.

Elapsed catalysts

• 2026-07-31 onward, undated — Any 424B7 prospectus supplement, marketed secondary or block trade under the effective resale shelf. Carries no calendar date and can land on any session. (passed 26d ago)
• Undated, post-2026-08-21 — Target or rating revisions from the two analysts who have not moved since KeyBanc's upgrade. J.P. Morgan's $7 Sell has stood since 2026-02-23; William Blair maintained Hold on 2026-05-06. (passed 5d ago)

What Would Change Our Mind

The structure this read rests on is the reclaim of the $10.50 shelf on the 2026-08-21 weekly settlement. Losing it again — a weekly close below $10.50 — puts the late-July high back on record as the top of the post-sanctions recovery leg and leaves the August break as the trend, not a shakeout. On the fundamentals, the 2026-09-08 print resolves three things that would each break the leg independently: FY2026 adjusted EBITDA below the $85M guide floor, an FY2027 adjusted-EBITDA guide whose midpoint does not exceed FY2026, or ending census below the 7,900 low end. A 424B7 priced beneath the prevailing quote, or a Schedule 13D/G amendment showing a reduced TCO Group Holdings stake, would put a clearing price on the registered block and change the tradable remainder. An 8-K or CMS notice disclosing an enrollment freeze at any of the 20 centers is the fastest single break available. In the other direction: if the September print draws no target increases from the remaining covering analysts, the $7 end of the range stays intact below the market and the KeyBanc call is left unconfirmed by anyone else.

Correlation Notes

• Capitated-risk healthcare. Medical-loss-ratio guidance from UNH, HUM, CNC and ELV moves the multiple on this complex independently of InnovAge's own execution; INNV's revenue is Medicare/Medicaid capitation for a dual-eligible, nursing-home-qualified population.
• The regulatory input is idiosyncratic, not sector beta: CMS sanctions and enrollment freezes are center-level and name-specific, and are the mechanism that broke this equity in 2021–2022.
• Float behaviour is small-cap despite a $1.39B market capitalisation at the 2026-08-11 close, because 83.2% of shares outstanding sit with one controlling holder as of 2026-04-30. Moves in either direction are amplified by the tradable remainder.
• Analyst coverage is three names. Single upgrades therefore carry more headline weight here than they would on a broadly covered mid-cap, which cuts both ways.